Core Viewpoint - Zhonghui Biotech-B (02627) saw a stock increase of over 7%, currently trading at 50.6 HKD with a transaction volume of 13.64 million HKD, following the announcement of its new drug clinical trial approval for a recombinant respiratory syncytial virus vaccine [1] Group 1 - The company announced that its self-developed recombinant respiratory syncytial virus vaccine (CHO cells) has received approval for its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) in China [1] - The vaccine's IND application has also been approved by the U.S. Food and Drug Administration (FDA) [1] - The vaccine utilizes CHO cells to express modified pre-F proteins, and the company has developed a high-yield monoclonal cell line capable of stably expressing pre-F proteins [1] Group 2 - In preclinical studies, the vaccine demonstrated higher pre-F expression levels, better thermal stability, and superior immunogenicity compared to existing recombinant RSV vaccines on the market [1]
港股异动 | 中慧生物-B(02627)涨超7% 重组呼吸道合胞病毒疫苗IND申请中美双报获批